Skip to Content
Developmental Therapeutics Program (DTP)
Last Updated: 04/02/15

BTB Growth Assay Data

The Biological Testing Branch [BTB] identifies growth characteristics for human tumor cell lines by implanting various cell concentrations into Athymic Nude, Severe Combined Immunodeficient [SCID], or Non-Obese Diabetic [NOD] SCID mice. The implanted animals are monitored for tumor growth at specific time points [on average twice weekly] using in situ caliper measurements. At the end of the experiment, the tumor weights are calculated [length x width x width / 2] and recorded in milligrams. The averages have been plotted [with standard error bars] to evaluate the growth characteristics and suitability for preclinical anticancer drug studies. This list is not comprehensive and additional cell lines [historical and future] will be added as data is compiled.

All of the following documents are in Adobe PDF format.

Cell Line Name Origin Animal Strain Route of Implantation
PDF Text Only
786-0 786-0 Human Renal nu/nu NCr Subcutaneous
A-375 A-375 Human Melanoma nu/nu NCr Subcutaneous
ACHN ACHN Human Renal NOD.SCID Subcutaneous
BT-474 BT-474 Human Breast nu/nu NCr Mammary Fat Pad
CCRF-CEM CCRF-CEM Human Lymphoma SCID Subcutaneous
COLO 205 COLO 205 Human Colon nu/nu NCr Subcutaneous
EKVX EKVX Human Lung [Non Small Cell] SCID Subcutaneous
HCC 1954 HCC 1954 Human Breast SCID Mammary Fat Pad
HCC 2998 HCC 2998 Human Colon nu/nu NCr Subcutaneous
HL-60 HL-60 Human Leukemia SCID Subcutaneous
IGR-OV1 IGR-OV1 Human Ovarian nu/nu NCr and SCID Subcutaneous
K-562 K-562 Human Leukemia SCID Subcutaneous
KM-12 KM-12 Human Colon nu/nu NCr Subcutaneous
LOX IMVI LOX IMVI Human Melanoma nu/nu NCr Subcutaneous
LS174T LS174T Human Colon nu/nu NCr Subcutaneous
M14 M14 Human Melanoma nu/nu NCr Subcutaneous
MDA-MB-231T MDA-MB-231T Human Breast nu/nu NCr Subcutaneous
MDA-MB-468 MDA-MB-468 Human Breast SCID Mammary Fat Pad
MOLT-4 MOLT-4 Human Leukemia SCID Subcutaneous
NCI-H226 NCI-H226 Human Lung [Non Small Cell] nu/nu NCr Subcutaneous
OVCAR-8 OVCAR-8 Human Ovarian nu/nu NCr Subcutaneous
RXF-631 RXF-631 Human Renal nu/nu NCr Subcutaneous
SK-MEL-5 SK-MEL-5 Human Melanoma nu/nu NCr Subcutaneous
SN12C SN12C Human Renal nu/nu NCr Subcutaneous
SW-620 SW-620 Human Colon nu/nu NCr Subcutaneous
U251 U251 Human Glioma nu/nu NCr Subcutaneous

Plowman J., Dykes D.J., Hollingshead M., Simpson-Herren L., Alley M.C. Human tumor xenograft models in NCI drug development Teicher B. eds. Anticancer Drug Development Guide: Preclinical Screening, Clinical Trials, and Approval: 101-125, Humana Press Inc. Totowa, NJ 1997.

About the Branch Chief

Dr. Melinda Hollingshead has served as Chief of the Biological Testing Branch at NCI since 2005. The Biological Testing Branch (BTB) establishes patient derived xenograft (PDX) models, isolates cell lines from PDX models and conducts preclinical anti-cancer drug evaluations in relevant rodent models. Additionally, the BTB manages the distribution of cell lines and tumor samples from the DCTD Repository. More…